Q: What was the major outcome/teaching point from ONTARGET study?

Answer: It is well know that ACE inhibitor drugs slows the progression of diabetic nephropathy. The major outcome of ONTARGET study was that, angiotensin receptor blockers (ARBs), have a similar benefit. However, combination therapy worsen renal outcomes, such as increasing serum creatinine and causing a greater decline in estimated glomerular filtration rate (eGFR).

Reference:

1. The ONTARGET Investigators; Yusuf, S; Teo, KK; Pogue, J; Dyal, L; Copland, I; Schumacher, H et al. (2008). "Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events". New England Journal of Medicine 358 (15): 1547–59.